01 May 2025:Haleon plc (the "Company" or "Haleon") today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 28 March 2025 (the "Buyback Programme").
Date of purchase:
30 April 2025
Number of Shares purchased:
856,851
Highest price paid per share (p):
377.30
Lowest price paid per share (p):
370.00
Volume weighted average price paid per share (p):
373.28
Following the settlement of the above, the Company's registered share capital is 9,020,990,697 ordinary shares of £0.01 each, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 9,016,910,492 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at:www.haleon.com/investors.
Enquiries
Investors
Media
Jo Russell
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel
+44 7552 484646
Victoria Durman
+44 7894 505730
Emma White
+44 7823 523562
Email:investor-relations@haleon.com
Email:corporate.media@haleon.com
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visitwww.haleon.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSKBLFXEZLLBBL
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
